CMS subsidiary Dermavon gets China approval for additional Lumirix indication
CMS says its subsidiary Dermavon has received approval in China for an additional indication of Lumirix(R) for atopic dermatitis (AD).
SHENZHEN, CHINA, Sept 4, 2026 - (ACN Newswire) - China Medical System Holdings Limited ("CMS" or the "Group") said its subsidiary Dermavon Holdings Limited ("Dermavon"), a pharmaceutical company focused on skin health and seeking a separate listing, has received approval in China for an additional indication for Lumirix. The approval covers the treatment of 4 types of indications in patients 2026.